Pro zobrazení tohoto obsahu je třeba být přihlášen.
Categories for Uncategorized
PHASE III MONALEESA-7 TRIAL OF PREMENOPAUSAL PATIENTS WITH HR+/HER2− ADVANCED BREAST CANCER TREATED WITH ENDOCRINE THERAPY ± RIBOCICLIB: OVERALL SURVIVAL RESULTS
19 srpna, 2020 12:54 pmMeeting 2019 ASCO® Annual Meeting Category Breast Cancer – Metastatic / Hormone Receptor-Positive Type Oral Abstract Session (Tuesday,...
CAPIVASERTIB (AZD5363) PLUS FULVESTRANT VERSUS PLACEBO PLUS FULVESTRANT AFTER RELAPSE OR PROGRESSION ON AN AROMATASE INHIBITOR IN METASTATIC ER-POSITIVE BREAST CANCER (FAKTION): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE II TRIAL
19 srpna, 2020 12:54 pmMeeting 2019 ASCO® Annual Meeting Category Breast Cancer – Metastatic Type Oral Abstract Session (Tuesday, June 4, 2019)...
IMPASSION130: UPDATED OVERALL SURVIVAL (OS) FROM A GLOBAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III STUDY OF ATEZOLIZUMAB (ATEZO) + NAB-PACLITAXEL (NP) IN PREVIOUSLY UNTREATED LOCALLY ADVANCED OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER (MTNBC)
19 srpna, 2020 12:54 pmMeeting 2019 ASCO® Annual Meeting Category Breast Cancer – Metastatic Type Oral Abstract Session (Tuesday, June 4, 2019)...
SOPHIA PRIMARY ANALYSIS: A PHASE 3 (P3) STUDY OF MARGETUXIMAB (M) + CHEMOTHERAPY (C) VERSUS TRASTUZUMAB (T) + C IN PATIENTS (PTS) WITH HER2+ METASTATIC (MET) BREAST CANCER (MBC) AFTER PRIOR ANTI-HER2 THERAPIES (TX)
19 srpna, 2020 12:54 pmMeeting 2019 ASCO® Annual Meeting Category Breast Cancer – Metastatic Type Oral Abstract Session (Tuesday, June 4, 2019)...
Adding Ribociclib to First-Line Endocrine Therapy Significantly Improves Survival for Pre-Menopausal Women with Advanced Breast Cancer
19 srpna, 2020 12:54 pmJune 1, 2019 “Advanced breast cancer in pre-menopausal women can be very aggressive. It is important and encouraging to...
Novinky z výročního zasedání ASCO® 2019 v léčbě karcinomu prsu
19 srpna, 2020 12:54 pmLetošní Annual Meeting ASCO® 2019 nepřinesl v léčbě karcinomu žádné převratné výsledky. Je důležité zdůraznit, že mravenčí prací jednotlivých výzkumných týmů...
BRIGATINIB IN PRETREATED PATIENTS WITH ALK-POSITIVE ADVANCED NSCLC
19 srpna, 2020 12:54 pmMeeting 2019 ASCO® Annual Meeting Category Lung Cancer – Non-Small Cell Metastatic Type Poster Session (Monday, June 2,...
PRELIMINARY RESULTS OF SINGLE ARM PHASE 2 TRIAL OF BRIGATINIB IN PATIENTS (PTS) WITH PROGRESSION DISEASE (PD) AFTER NEXT-GENERATION (NG) ANAPLASTIC LYMPHOMA KINASE (ALK) TYROSINE KINASE INHIBITORS (TKIS) IN ALK + NON-SMALL CELL LUNG CANCER (NSCLC)
19 srpna, 2020 12:54 pmMeeting 2019 ASCO® Annual Meeting Category Lung Cancer – Non-Small Cell Metastatic Type Poster Session (Monday, June 2,...
CLINICAL ACTIVITY AND TOLERABILITY OF BLU-667, A HIGHLY POTENT AND SELECTIVE RET INHIBITOR, IN PATIENTS (PTS) WITH ADVANCED RET-FUSION+ NON-SMALL CELL LUNG CANCER (NSCLC)
19 srpna, 2020 12:54 pmMeeting 2019 ASCO® Annual Meeting Category Lung Cancer – Non-Small Cell Metastatic Type Oral Abstract Session (Monday, June...
CAPMATINIB (INC280) IN METΔEX14-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): EFFICACY DATA FROM THE PHASE II GEOMETRY MONO-1 STUDY
19 srpna, 2020 12:54 pmMeeting 2019 ASCO® Annual Meeting Category Lung Cancer – Non-Small Cell Metastatic Type Oral Abstract Session (Monday, June...